Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Association of cyclooxygenase-2 genetic variant with cardiovascular disease.

Ross S, Eikelboom J, Anand SS, Eriksson N, Gerstein HC, Mehta S, Connolly SJ, Rose L, Ridker PM, Wallentin L, Chasman DI, Yusuf S, Paré G.

Eur Heart J. 2014 Sep 1;35(33):2242-8a. doi: 10.1093/eurheartj/ehu168. Epub 2014 May 5.

2.
3.

Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke.

Lemaitre RN, Rice K, Marciante K, Bis JC, Lumley TS, Wiggins KL, Smith NL, Heckbert SR, Psaty BM.

Atherosclerosis. 2009 Jun;204(2):e58-63. doi: 10.1016/j.atherosclerosis.2008.10.011. Epub 2008 Nov 1.

4.

Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study.

Lee CR, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC.

Clin Pharmacol Ther. 2008 Jan;83(1):52-60. Epub 2007 May 9.

5.

Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis.

Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ.

Circulation. 2000 Aug 22;102(8):840-5.

6.

In vivo production of prostacyclin and thromboxane in patients with acute myocardial infarction.

Henriksson P, Wennmalm A, Edhag O, Vesterqvist O, Green K.

Br Heart J. 1986 Jun;55(6):543-8.

7.

Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.

Capone ML, Tacconelli S, Sciulli MG, Grana M, Ricciotti E, Minuz P, Di Gregorio P, Merciaro G, Patrono C, Patrignani P.

Circulation. 2004 Mar 30;109(12):1468-71. Epub 2004 Mar 22.

8.

Interaction between COX-1 and COX-2 Variants Associated with Aspirin Resistance in Chinese Stroke Patients.

Yi X, Cheng W, Lin J, Zhou Q, Wang C.

J Stroke Cerebrovasc Dis. 2016 Sep;25(9):2136-44. doi: 10.1016/j.jstrokecerebrovasdis.2016.05.039. Epub 2016 Jun 16.

PMID:
27318652
9.

Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk.

Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg PG, Montalescot G, Johnston SC, Steinhubl SR, Mak KH, Easton JD, Hamm C, Hu T, Fox KA, Topol EJ; Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators.

Circulation. 2008 Oct 21;118(17):1705-12. doi: 10.1161/CIRCULATIONAHA.108.768283. Epub 2008 Oct 6.

10.

Association of COX-2 rs20417 with aspirin resistance.

Sharma V, Kaul S, Al-Hazzani A, Alshatwi AA, Jyothy A, Munshi A.

J Thromb Thrombolysis. 2013 Jan;35(1):95-9. doi: 10.1007/s11239-012-0777-8.

PMID:
22763923
11.

Thromboxane and prostacyclin biosynthesis in patients with acute spontaneous intracerebral hemorrhage.

Saloheimo P, Juvela S, Riutta A, Pyhtinen J, Hillbom M.

Thromb Res. 2005;115(5):367-73.

PMID:
15733969
12.

Implications of the prognostic importance of exercise-induced thromboxane formation in survivors of an acute myocardial infarction.

Rasmanis G, Vesterqvist O, Gréen K, Henriksson P.

Prostaglandins. 1995 Apr;49(4):247-53.

PMID:
7667506
13.

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.

McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA.

Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):272-7. Erratum in: Proc Natl Acad Sci U S A 1999 May 11;96(10):5890.

14.

Functional rs20417 SNP (-765G>C) of cyclooxygenase-2 gene does not predict the risk of recurrence of ischemic events in coronary patients: results of a 7-year prospective study.

Montali A, Barillà F, Tanzilli G, Vestri A, Fraioli A, Gaudio C, Martino F, Mezzetti A, Cipollone F, Arca M.

Cardiology. 2010;115(3):236-42. doi: 10.1159/000298880. Epub 2010 Mar 19.

PMID:
20299798
15.

Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study.

Mills JL, DerSimonian R, Raymond E, Morrow JD, Roberts LJ 2nd, Clemens JD, Hauth JC, Catalano P, Sibai B, Curet LB, Levine RJ.

JAMA. 1999 Jul 28;282(4):356-62.

PMID:
10432033
16.

Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization.

Frelinger AL 3rd, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD.

Circulation. 2009 Dec 22;120(25):2586-96. doi: 10.1161/CIRCULATIONAHA.109.900589. Epub 2009 Dec 7.

17.

Prostacyclin, thromboxane A and the effect of low-dose ASA in pregnancies at high risk for hypertensive disorders.

Vainio M, Riutta A, Koivisto AM, Mäenpää J.

Acta Obstet Gynecol Scand. 2004 Dec;83(12):1119-23.

PMID:
15548142
18.

A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke.

Cipollone F, Toniato E, Martinotti S, Fazia M, Iezzi A, Cuccurullo C, Pini B, Ursi S, Vitullo G, Averna M, Arca M, Montali A, Campagna F, Ucchino S, Spigonardo F, Taddei S, Virdis A, Ciabattoni G, Notarbartolo A, Cuccurullo F, Mezzetti A; Identification of New Elements of Plaque Stability (INES) Study Group.

JAMA. 2004 May 12;291(18):2221-8.

PMID:
15138244
19.

Experimental fat embolism induces urine 2,3-dinor-6-ketoprostaglandin F1alpha and 11-dehydrothromboxane B2 excretion in pigs.

Rautanen M, Gullichsen E, Riutta A, Kuttila K, Mucha I, Nelimarkka O, Niinikoski J.

Crit Care Med. 1997 Jul;25(7):1215-21.

PMID:
9233750
20.

The COX-2 rs20417 polymorphism and risk of coronary artery disease: evidence from 17,621 subjects.

Wang H, Fu Y, Liu D, Zhang M, Zhang G, Wu W, Yang S, Li C, Zhang H.

Heart Lung Circ. 2014 Jun;23(6):572-7. doi: 10.1016/j.hlc.2014.01.002. Epub 2014 Jan 22. Review.

PMID:
24513487

Supplemental Content

Support Center